Life Sciences INDUSTRIES

Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.


Recognized as a leading life sciences practice, WilmerHale has represented life sciences clients across the United States and Europe for more than four decades. From biotechnology, pharmaceutical, diagnostic and medical device companies at all stages of growth to other institutions in the space, including venture capitalists, investment banks, universities and others, we understand the business of our life sciences clients and the changing regulatory and competitive demands they face.

Contacts

Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

stuart.falber@wilmerhale.com

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)

belinda.juran@wilmerhale.com

Der Marderosian, Lia

Lia Der Marderosian

Co-Chair, Corporate Practice Group

+1 617 526 6982 (t)

lia.dermarderosian@wilmerhale.com

johnson-brian.jpg

Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

brian.johnson@wilmerhale.com

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)

steven.singer@wilmerhale.com

Capabilities

WilmerHale's Life Sciences Practice has extraordinary range, and the majority of our lawyers devote a significant portion of their practice to areas critical to life sciences clients. The firm's multi-disciplinary teams work seamlessly to handle a broad range of matters for clients, including corporate finance, licensing and strategic alliances, litigation, mergers and acquisitions, intellectual property, Food and Drug Administration (FDA), competition and other regulatory matters, and securities fraud. Our lawyers advise on venture financings, public offerings, mergers and acquisitions, and licensing agreements and collaborations; protect clients' innovations through patent prosecution and portfolio development; and defend their interests in enterprise-critical patent litigation. We also represent life sciences clients in dealings with the United States and other governments on regulatory matters, including issues before the FDA and other agencies, merger clearance and enforcement actions, and public policy and strategy. Read about some of our recent life sciences transactions.

Our Life Sciences Practice includes corporate lawyers who have helped thousands of entrepreneurs successfully launch their businesses; raise billions in financing; and take their companies to sale, the public markets and/or through drug commercialization. We have a longstanding tradition of representing emerging companies and entrepreneurs across industries, and routinely offer the strategic advice and sharp business perspectives that are critical to our clients' success. Learn about our startup practice at WilmerHaleLaunch.com.

Publications & News

View

July 20, 2017

WilmerHale Earns Win at Federal Circuit on Behalf of Takeda in Hatch-Waxman Litigation

The appeals court reversed a district court finding of patent invalidity based on obviousness and remanded the case with instructions to enter judgment in favor of Takeda.

July 6, 2017

WilmerHale Represents Aileron Therapeutics in IPO

Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled peptides for cancers and other diseases, announced the pricing of its initial public offering.

June 13, 2017

Hyalex Orthopaedics Raises $16 Million Series A Financing

WilmerHale client Hyalex Orthopaedics, a medical device company advancing new products that feature HYALEX™ technology, a synthetic polymer that mimics cartilage, announced that it has raised $16 million in Series A financing.

June 9, 2017

The Legal 500 United States 2017 Recognizes 125 WilmerHale Lawyers Across 28 Practice Areas

The Legal 500 United States has released its 2017 rankings, recommending 125 WilmerHale lawyers—including 12 who are named to its elite “Leading Lawyers” list and two on its “Next Generation Lawyers” list—and 28 practice areas in its 11th edition.

June 8, 2017

WilmerHale Partners and Practices Named Among Managing Intellectual Property's 2017 IP Stars

IP Stars identifies lawyers based on their practice and industry experience, and recommendations from their peers and clients.

June 7, 2017

Selected 2017 Life Sciences Transactions

Recognized both globally and nationally for its leading life sciences practice, WilmerHale has more than four decades of experience representing biotechnology, pharmaceutical and medical device companies at all stages of growth, as well as venture capitalists and investment banks.

May 26, 2017

WilmerHale Lawyers and Practices Recognized in 2017 Edition of Chambers USA

Chambers and Partners announced its rankings for the 2017 edition of Chambers USA: America's Leading Lawyers for Business, with WilmerHale listed among the nation's best in 50 practice area categories. Chambers also ranked 86 WilmerHale lawyers as leaders in their respective fields.

May 18, 2017

Nations Press for International Restrictions to Govern Genetic Sequence Data

As various nations consider application of international ABS requirements to GSD, research organizations and synthetic biology companies should closely follow these developments to determine how they may impact their use of GSD. Moreover, those accessing GSD should consider, if possible, the extent to which unilateral ABS agreements requirements may govern their use of such information.

May 17, 2017

WilmerHale Ranks Among Top Three Life Sciences Law Firms for Second Consecutive Year

The index—launched last year by Lake Whillans and Breaking Media (publisher of MedCity News and Above the Law)—identifies which law firms are the most active and relevant for life sciences companies.

May 16, 2017

Finding a Way Through a Tight Deal Space

WilmerHale's Life Sciences Group Co-Chairs Belinda Juran and Stuart Falber share trends they are seeing in the life sciences industry regarding acquisitions and IPOs in an interview with Breaking Media's Above the Law.

Recognition

  • Chambers USA: America's Leading Lawyers for Business - Named WilmerHale a top law firm for life sciences from 2007-2017 with sources saying our attorneys are "consistently excellent," "very responsive" and "continue to stand out," and that WilmerHale is "a very strong firm" that is "in the top 1%" in the area of life sciences. 
  • Chambers Global - Recognized WilmerHale as a leader in life sciences from 2013-2017 and quoted sources as saying that the firm has an "outstanding US practice coupled with international reach" and "a team of lawyers with a valuable scientific background."
  • Chambers Europe - Recognized WilmerHale as a leader in life sciences in Germany in its 2013-2016 editions.
  • Lake Whillans - The Life Sciences Law Firm Index included WilmerHale among the top three best life sciences law firms (2016, 2017), as the top firm for startup work (2017), among the top 10 deal firms (2017), the top two patent law firms (2016) and top 10 firms for thought leadership (2016).
  • Law360 - Named WilmerHale a Technology Practice Group of the Year for 2016 and a Life Sciences Practice Group of the Year for 2013 in its annual rankings, which recognize firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year.
  • LMG Life Sciences - Ranked the firm in its 2012-2016 editions in the areas of patent prosecution, patent strategy and management, general patent litigation, Hatch-Waxman patent litigation, corporate, licensing and collaboration, M&A, venture capital and white collar/government investigations, and named WilmerHale a "Lifecycle Firm." In 2013, WilmerHale was named the winner of the "Canadian Impact Deals of the Year" award, in recognition of its representation of Enobia Pharma in its acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP - Recognized WilmerHale as one of the best in the United States for life sciences from 2013-2016. In 2013, 2016 and 2017, WilmerHale was named the "Patent Contentious Firm of the Year" and in 2013, the "Pharmaceutical IP Litigation Firm of the Year."
  • The American Lawyer - Placed WilmerHale on its 2016 "A-List" as one of the United States' leading law firms, marking the 13th year the firm received that recognition.
  • The American Lawyer - Named WilmerHale the 2014 IP Litigation Department of the Year and a finalist for its 2016 IP Litigation Department of the Year. The firm has been named a winner twice and a finalist six times since the contests launch in 2004.
  • The BTI Consulting Group Inc. - Named WilmerHale among the top 10 law firms for having strong and lasting client relationships with the pharma industry in its BTI Power Rankings 2016 report.
  • The Legal 500 US - Ranked WilmerHale among the top law firms for life sciences from 2013-2017 with sources saying the firm "brings a great deal of experience to any situation" and "has access to additional expertise/resources to help solve any problem."
  • The National Law Journal - Named WilmerHale to its 2012-2015 Intellectual Property Hot List, which honors firms that demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News - Best Lawyers® - Recognized the firm in its 2014-2017 "Best Law Firms" lists in the first tier nationally for biotechnology law, corporate law, intellectual property litigation, patent law, securities and venture capital law. In 2017, WilmerHale received first-tier metropolitan rankings in Boston intellectual property litigation, patent law, technology law and venture capital law; in Colorado for intellectual property litigation; in New York for biotechnology law and corporate law; in San Jose for patent litigation; and in Washington DC for intellectual property litigation.